Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Deubiquitinating enzymes: Promising targets for drug resistance
Fujing Ge, Yuekang Li, Tao Yuan, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 9, pp. 2603-2613
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Advancing Strategies for Proteolysis-Targeting Chimera Design
Minglei Li, Ying Zhi, Bo Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2308-2329
Closed Access | Times Cited: 46
Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options
Hongli Gao, Zhuo Xi, Jingwei Dai, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 16
Ubiquitination and deubiquitination: Implications on cancer therapy
Gunjan Dagar, Rakesh Kumar, Kamlesh Yadav, et al.
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms (2023) Vol. 1866, Iss. 4, pp. 194979-194979
Closed Access | Times Cited: 34
Recent advances in the development of deubiquitinases inhibitors as antitumor agents
Lili Zheng, Liting Wang, Ye-Wei Pang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 266, pp. 116161-116161
Closed Access | Times Cited: 12
Role of protein degradation systems in colorectal cancer
Zihan Cui, Mingqi Cong, Shengjie Yin, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1
Ryan D. Imhoff, Rishi Patel, Muhammad Hassan Safdar, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4496-4524
Closed Access | Times Cited: 7
USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells
Janardhan Keshav Karapurkar, Jencia Carminha Colaco, Bharathi Suresh, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 6
PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
Xiaohui Ren, Lijuan Wang, Likun Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
The deubiquitinase EIF3H promotes hepatocellular carcinoma progression by stabilizing OGT and inhibiting ferroptosis
Jianing Tang, Guo Long, Xuanxuan Li, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 13
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization
Jiaqi Liu, Kaikai Wang, Qian Zhu, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 4
Open Access | Times Cited: 4
USP13: A therapeutic target for combating tumorigenesis and antitumor therapy resistance
Lina Yi, Akezhouli Shahatiaili, Lin Zhang, et al.
International Journal of Biological Macromolecules (2025), pp. 140608-140608
Closed Access
Role of Ubiquitination-driven Metabolisms in Oncogenesis and Cancer Therapy
Dongqin Yang, Can Yang, Linlin Huang, et al.
Seminars in Cancer Biology (2025)
Closed Access
Unraveling the role of deubiquitinating enzymes on cisplatin resistance in several cancers
S. Jin, Kwang‐Hyun Baek
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189297-189297
Closed Access
USP18 Confers Paclitaxel Resistance in Non‐Small Cell Lung Cancer by Stabilizing SHANK1 Expression Via Deubiquitination
Lixun Chai, Yanlong Sun, Yunfei Wang, et al.
Journal of Biochemical and Molecular Toxicology (2025) Vol. 39, Iss. 3
Closed Access
Targeting the JAK2–STAT3–UCHL3–ENO1 axis suppresses glycolysis and enhances the sensitivity to 5-FU chemotherapy in TP53-mutant colorectal cancer
Haisong Xin, Zitong Zhao, Shichao Guo, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Emerging role of deubiquitinases in modulating cancer chemoresistance
Sukeerthi Dasharathy, Pranay, Santhosh K Devdas, et al.
Drug Discovery Today (2025), pp. 104339-104339
Closed Access
Huib32: A Potent and Selective USP32 Inhibitor Modulating Endosomal Processes and Advancing Cell-Permeable USP32 Probes
Stephan Scherpe, Vito Pol, Raymond Kooij, et al.
(2025)
Open Access
USP46 enhances tamoxifen resistance in breast cancer cells by stabilizing PTBP1 to facilitate glycolysis
Shun Gao, Yuan Wang, Yingkun Xu, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 3, pp. 167011-167011
Open Access | Times Cited: 2
Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation
Tengda Li, Maowen Huang, Ning Sun, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
Ubiquitin specific peptidase 3: an emerging deubiquitinase that regulates physiology and diseases
Yizhu Wang, Yanlong Shi, Kaiyi Niu, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
USP26 as a hepatitis B virus-induced deubiquitinase primes hepatocellular carcinogenesis by epigenetic remodeling
Mengru Ma, Yi Lian, Yifei Pei, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe
Julie M. Vancoppenolle, Simone N. Koole, James F. O’Mahony, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 8, pp. 103620-103620
Open Access | Times Cited: 2
[Ubiquitin-specific protease 42 regulates osteogenic differentiation of human adipose-derived stem cells].
Yuan Pan, Hang Gu, Xiao Han, et al.
PubMed (2024) Vol. 56, Iss. 1, pp. 9-16
Closed Access
Unraveling role of ubiquitination in drug resistance of gynecological cancer
Yu Li
American Journal of Cancer Research (2024) Vol. 14, Iss. 5, pp. 2523-2537
Open Access
Page 1 - Next Page

Scroll to top